Inhibition of human cytochrome P450 isoforms by nonnucleoside reverse transcriptase inhibitors

Journal of Clinical Pharmacology

Volumn 41, Issue 1, 2001, Pages 85-91

  von Moltke, Lisa L ^a,b,c   Greenblatt, David J ^a,b,c   Granda, Brian W ^a,b,c   Giancarlo, Gina M ^a,b,c   Duan, Su Xiang ^a,b,c   Daily, Johanna P ^a,b,c   Harmatz, Jerold S ^a,b,c   Shader, Richard I ^a,b,c  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TUFTS MEDICAL CENTER   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 3A; CYTOCHROME P450 ISOENZYME; DEBRISOQUINE 4 HYDROXYLASE; DELAVIRDINE; EFAVIRENZ; MEPHENYTOIN; NEVIRAPINE; PHENACETIN O DEETHYLASE; PHENYTOIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; TOLBUTAMIDE; WARFARIN;

ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG CLEARANCE; DRUG EFFECT; DRUG INHIBITION; DRUG TRANSFORMATION; ENZYME INDUCTION; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER MICROSOME;

ANTI-HIV AGENTS; CYTOCHROME P-450 ENZYME SYSTEM; DELAVIRDINE; HUMANS; HYDROLYSIS; INHIBITORY CONCENTRATION 50; ISOENZYMES; MICROSOMES, LIVER; NEVIRAPINE; OXAZINES; REVERSE TRANSCRIPTASE INHIBITORS; TRIAZOLAM;

EID: 0034747669     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/00912700122009728     Document Type: Article

References (48)

1. Antiretroviral therapy for HIV infection
2. Antiretroviral therapy for patients with HIV disease
3. Managing resistance to anti-HIV drugs: An important consideration for effective disease management
4. Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection
5. HIV-protease inhibitors
6. Protease inhibitors in patients with HIV disease: Clinically important pharmacokinetic considerations
7. Ritonavir: Clinical pharmacokinetics and interactions with other anti-HIV agents
8. Pharmacokinetics of protease inhibitors and drug interactions with psychoactive drugs
9. Alprazolam metabolism in vitro: Studies of human, monkey, mouse, and rat liver microsomes
10. Inhibitors of alprazolam metabolism in vitro: Effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine
11. Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake-inhibitor antidepressants, and by quinidine and ketoconazole: A model system to predict drug interactions in vivo
12. Phenacetin O-deethylation by human liver microsomes in vitro: Inhibition by chemical probes, SSRI antidepressants nefazodone, and venlafaxine
13. Human cytochromes P450 mediating phenacetin O-deethylation in vitro: Validation of the high affinity component as an index of CYP1A2 activity
14. Relative quantities of catalytically active CYP 2C9 and 2C19 in human liver microsomes: Application of the relative activity factor approach
15. Characterization of six in vitro reactions mediated by human cytochrome P450: Application to the testing of cytochrome P450-directed antibodies
16. Metabolism of dextromethorphan in vitro: Involvement of cytochromes P450 2D6, 3A3/4, with a possible role of 2E1
17. Multiple human cytochromes contribute to biotransformation of dextromethorphan in vitro: Role of CYP2C9, CYP2C19, CYP2D6, and CYP3A
18. Triazolam biotransformation by human liver microsomes in vitro: Effects of metabolic inhibitors, and clinical confirmation of a predicted inter-action with ketoconazole
19. Inhibition of triazolam hydroxylation by ketoconazole itraconazole hydroxyitraconazole and fluconazole in vitro
20. Midazolam and triazolam biotransformation in mouse and human liver microsomes: Relative contribution of CYP3A and CYP2C9 isoforms
21. Mechanism-based enzyme inactivators
22. Inhibition of triazolam clearance by macrolide antimicrobial agents: In vitro correlates and dynamic consequences
23. Potent mechanism-based inhibition of human CYP3A in vitro by amprenavir and ritonavir: Comparison with ketoconazole
24. Protease inhibitors as inhibitors of human cytochromes P450: High risk associated with ritonavir
25. Five distinct human cytochromes mediate amitriptyline N-demethylation in vitro: Dominance of CYP 2C19 and 3A4
26. Effects of the antifungal agents on oxidative drug metabolism in humans: Clinical relevance
27. Citalopram and desmethylcitalopram in vitro: Human cytochromes mediating transformation, and cytochrome inhibitory effects
28. In vitro metabolism oftrazodone by CYP3A: Inhibition by ketoconazole and human immunodeficiency viral protease inhibitors
29. Pharmacokineticpharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition
30. Inhibition and induction of cytochrome P450 and the clinical implications
31. In vitro and in vivo drug interactions involving human CYP3 A
32. Integrated cytochrome P450 reaction phenotyping: Attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes
33. Pharmacokinetic and pharmacodynamic consequences of metabolism-based drug interactions with alprazolam, midazolam, triazolam
34. Prediction of pharmacokinetic alterations caused by drug-drug interactions: Metabolic interaction in the liver
35. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions
36. Can in vitro models predict drug interactions in vivo? A review of methods, problems, and successes
37. In vitro approaches to predicting drug interactions in vivo
38. Microsomal metabolism of delavirdine: Evidence for mechanism-based inactivation of human cytochrome P450 3A
39. Steady-state pharmacokinetics of delavirdine in HIV-positive patients: Effect on erythromycin breath test
40. Pharmacokinetic drug-drug interaction study of delavirdine and indinavir in healthy volunteers
41. Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450
42. Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone
43. Nevirapine-induced withdrawal symptoms in HIV patients on methadone maintenance programme: An alert
44. Methadone withdrawal when starting an antiretroviral regimen including nevirapine
45. Effect of ritonavir on the pharmacokinetics and pharmacodynamics of alprazolam (abstract A-59)
46. Alprazolam-ritonavir interaction: Implications for product labeling
47. Extensive impairment of triazolam and alprazolam clearance by short-term low-dose ritonavir: The clinical dilemma of concurrent inhibition and induction
48. Neither dapsone hydroxylation nor cortisol 6 beta-hydroxylation detects the inhibition of CYP3A4 by HIV-1 protease inhibitors